for patients with
severe genetic diseases.
bluebird announces completion of acquisition by global investment firms
We persist for patients and are committed to collaborating with the patient community
Setting the standard for gene therapy
Gene Addition Therapy: We’re building platforms with broad therapeutic potential because incremental improvements won’t do
For more than a decade, we’ve forged new paths for gene therapies and are improving and advancing at every step. We have the largest and deepest ex-vivo gene therapy data set in the world—driving the field forward. We are currently developing gene therapies for severe genetic diseases.